



%4a" HMD9G'C: 'B: 97 HCB'5 GGC7-5 H98' K #k-71 @H F9fGL' f7\ YW' U''h UHdd'nL'
None Unknown Colonized
Abscess, not skin Cellulitis Epidural Abscess Pyelonephritis Surgical incision infection
AV fistula/graft infection Chronic ulcer/wound (not decubitus) Meningitis Septic arthritis Surgical site infection (internal)
Bacteremia Decubitus/pressure ulcer Osteomyelitis Septic emboli Traumatic wound
Bursitis Empyema Peritonitis Septic shock Urinary tract infection
Catheter site infection (CVC) Endocarditis Pneumonia Skin abscess Other (specify):

%8" I B89F @MB; '7 CB8 #HCBG: f7\ YW' U''h UHdd'nL'
None Unknown
7 <FCB7' @ B; '8 -G95 G9'
Cystic fibrosis HIV infection AIDS/CD4 count < 200 Cerebral palsy Chronic cognitive deficit Dementia
Chronic pulmonary disease Primary immunodeficiency Transplant, hematopoietic stem cell Transplant, solid organ Epilepsy/seizure/seizure disorder Multiple sclerosis Neuropathy Parkinson's disease Other (specify):
7 <FCB7' A9H56 C @7' 8 -G95 G9
Diabetes mellitus With chronic complications
7 5F8-CJ5G7I @F' 8 -G95 G9'
CVA/Stroke/TIA Congenital heart disease Congestive heart failure Myocardial infarction Peripheral vascular disease (PVD)
; 5 GHFC-BH9GH5 @8 -G95 G9
Diverticular disease Inflammatory bowel disease Peptic ulcer disease Short gut syndrome
A A1 BC7CADFCA-G98 '7 CB8 #HCB
HIV infection AIDS/CD4 count < 200 Primary immunodeficiency Transplant, hematopoietic stem cell Transplant, solid organ
@J9F' 8 -G95 G9
Chronic liver disease Ascites Cirrhosis Hepatic encephalopathy Variceal bleeding Hepatitis C Treated, in SVR Current, chronic
A5 @; B5 B7 M'
Malignancy, hematologic Malignancy, solid organ (non-metastatic) Malignancy, solid organ (metastatic)
B9I FC @; '7 CB8 #HCB'
Cerebral palsy Chronic cognitive deficit Dementia Epilepsy/seizure/seizure disorder Multiple sclerosis Neuropathy Parkinson's disease Other (specify):
'D @; '5 G'D5F5 @G-G'
Hemiplegia Paraplegia Quadriplegia
G? -B' 7 CB8 #HCB'
Burn Decubitus/pressure ulcer Surgical wound Other chronic ulcer or chronic wound Other (specify):
CH-9F'
Connective tissue disease Obesity or morbid obesity Pregnant
MUGSI CONDITIONS'
Urinary tract problems/abnormalities Premature birth Spina bifida
RENAL DISEASE
Chronic kidney disease Lowest serum creatinine: mg/DL Unknown or not done

19. SUBSTANCE' I G9 OTHER SUBSTANCES: (Check all that apply)' None Unknown
8C7I A9BH98' I G9 8-GCF89F' fB1 8)561 G9. AC89' C: '89 @J9FM' f7\ YW' U''h UHdd'nL'
SMOKING: f7\ YW' U''h UHdd'nL'
None Unknown
Tobacco E-nicotine delivery system Marijuana
ALCOHOL ABUSE:
Yes No Unknown
Marijuana, cannabinoid (other than smoking) Opioid, DEA schedule I (e.g., heroin) Opioid, DEA schedule II-IV (e.g., methadone, oxycodone) Opioid, NOS Cocaine Methamphetamine Other (specify): Unknown substance
DUD or abuse IDU Skin popping Non-IDU Unknown
DUD or abuse IDU Skin popping Non-IDU Unknown
DUD or abuse IDU Skin popping Non-IDU Unknown
DUD or abuse IDU Skin popping Non-IDU Unknown
DUD or abuse IDU Skin popping Non-IDU Unknown
DUD or abuse IDU Skin popping Non-IDU Unknown
DUD or abuse IDU Skin popping Non-IDU Unknown
DUD or abuse IDU Skin popping Non-IDU Unknown
DUD or abuse IDU Skin popping Non-IDU Unknown
DUD or abuse IDU Skin popping Non-IDU Unknown
DURING THE CURRENT HOSPITALIZATION, DID THE PATIENT RECEIVE MEDICATION ASSISTED TREATMENT (MAT) FOR OPIOID USE DISORDER? Yes No N/A (patient not hospitalized or did not have DUD)

20. F-G? : 57 HCFG. f7\ YW' U''h UHdd'nL'
None Unknown
K 5 G'-B7-89BHGD97-A9B7C @7H98' 'CF'ACF9'75 @B85F'
85 MG'5: H9F' <CGD-H5 @58 A-GG-CB3
Yes No
DF9J-CI G' <CGD-H5 @N5 HCB' -B' H'K-9' M95F'69: CF9' 8-G7:
Yes No Unknown
IF YES, DATE OF DISCHARGE CLOSEST TO DISC: - -
OR, DATE UNKNOWN
Facility ID:
CJ9FB7 <HGH5M-B' @H7: 'B' H'K-9' M95F'69: CF9' 8-G7:
Yes No Unknown
Facility ID:
CJ9FB7 <HGH5M-B' @H57 <'B' H'K-9' M95F'69: CF9' 8-G7:
Yes No Unknown
Facility ID:
G' F; 9FM-B' H'K-9' M95F'69: CF9' 8-G7:
Yes No Unknown
71 FF9BH7 <FCB7' 8-5 @G-G.
Yes No Unknown
IF YES, TYPE: Hemodialysis Peritoneal Unknown
IF HEMODIALYSIS, TYPE OF VASCULAR ACCESS:
AV fistula/graft Hemodialysis central line Unknown
79BH5 @B9' -B'D @79' CB' H'K-9' 8-G7' f' D' HC' H'K-9' HA9' C: '
7C @7 HCB'ZCF' 5H5 BMHA9' -B' H'K-9' &75 @B85F'
85 MG'69: CF9' 8-G7.
Yes No Unknown
Check here if central line in place for > 2 calendar days:
I F-B5FM75H-9H9F' -B'D @79' CB' H'K-9' 8-G7' f' D' HC' H'K-9' HA9' C: '
7C @7 HCB'ZCF' 5H5 BMHA9' -B' H'K-9' &75 @B85F' 85 MG'69: CF9' 8-G7.
Yes No Unknown
IF YES, CHECK ALL THAT APPLY:
Indwelling Urethral Catheter Suprapubic Catheter Condom Catheter Other (specify):
5 BMCH-9F' -B8K9 @B; '89J-9' -B'D @79' CB' H'K-9' 8-G7' f' D' HC' H'K-9' HA9' C: '
7C @7 HCB'ZCF' 5H5 BMHA9' -B' H'K-9' &75 @B85F' 85 MG'69: CF9' 8-G7.
Yes No Unknown
IF YES, CHECK ALL THAT APPLY:
ET/NT Tube Gastrostomy Tube NG Tube Tracheostomy Nephrostomy Tube Other (specify):
PATIENT TRAVELED INTERNATIONALLY IN THE YEAR BEFORE DISC:
Yes No Unknown
COUNTRY: , ,

&1U" K97 <H. lbs. oz. OR
&1V" <97 <H. ft. in. OR
&1W' 6A= SSSSSSSS
kg Unknown cm Unknown Unknown
PATIENT HOSPITALIZED WHILE VISITING COUNTRY(IES) ABOVE:
Yes No Unknown



IFB971 @H F9G' CB@M &2" F97CF8 'H<9' 7C@CBM7 CI BH.

IFB971 @H F9G'CB@M & . G= BG5B8 'GMADHCAG'5GGC7-5H98 'K <K' I F-B9 71 @H F9"

Please indicate if any of the following symptoms were reported during the 5 day time period including the 2 calendar days before through the 2 calendar days after the DISC.

- BcbY □ I_b_bck b □ Costovertebral angle pain or tenderness □ Frequency □ Dysuria □ Suprapubic tenderness □ Fever [temperature ≥ 100.4 °F (38 °C)] □ Urgency □ Apnea □ Bradycardia □ Lethargy □ Vomiting

&4U" =G5BH A7FC6-5 @I G9'fW'CF CF5 @-B'H<9' '\$85MG'69: CF9'H<9'8<G7'8C7I A9BH983' □ Yes □ No □ Unknown

&4V" = 'M9GZ7 <9? '5 @@5BH A7FC6-5 @G1 G98 '-B'H<9' '\$85MG'69: CF9'H<9'8<G7 . f7\ YW_U''h UhUdd'nl'..... □ Unknown

- Amikacin □ Cefazolin □ Cefdinir □ Cefepime □ Cefiderocol □ Cefixime □ Cefotaxime □ Cefoxitin □ Cefpodoxime □ Ceftaroline □ Ceftriaxone □ Cefuroxime □ Cephalixin □ Ciprofloxacin □ Clarithromycin □ Clindamycin □ Dalbavancin □ Daptomycin □ Delafloxacin □ Doripenem □ Doxycycline □ Ertapenem □ Eravacycline □ Fidaxomicin □ Fosfomycin □ Gentamicin □ Imipenem/cilastatin □ Levofloxacin □ Linezolid □ Meropenem □ Meropenem/vaborbactam □ Metronidazole □ Moxifloxacin □ Nitrofurantoin □ Omadacycline □ Oritavancin □ Penicillin □ Piperacillin/tazobactam □ Polymyxin B □ Polymyxin E (colistin) □ Rifaximin □ Tedizolid □ Telavancin □ Tigecycline □ Tobramycin □ Trimethoprim □ Trimethoprim/sulfamethoxazole □ Vancomycin □ IV □ PO □ Other (specify): □ Other (specify):

REMINDER: Any prior antimicrobial use that is not noted above should be documented in the other (specify) field.

&5a" DID 'H<9' D5H9BH HAVE A POSITIVE TEST(S) FOR 'G5FGI7 cJ1& fA C @71 @ F'5 G65 MZG9 FC @; MCF' CH<9F'7CB: -F A5 HCFMH9GH'CB'CF' 69: CF9'H<9'8<G7 3'

- Yes □ No □ Unknown

&5b. IF YES, COMPLETE TABLE BELOW:

Table with 3 columns: Test description, Specimen collection date, Test type. Rows for 'FIRST positive test for SARS-CoV-2 on or before the DISC' and 'MOST RECENT positive test for SARS-CoV-2 on or before the DISC'.

&5W7 CJ-8 IB9H75 G9' -8.

&5X" BB8 GG-8 g'fD @5 G9' DFCJ-89'5H' @5 GH'CB9' C: 'H<9' : C @C'K -B; 'K <9B'5 DD @7 56 @L

@WU'cUgY-8. @WU'rYw6fX'-8. GHUH'VUgY'X'YbHjZ'Yf. @[UWhVUgY'X'YbHjZ'Yf. CDC 2019-nCOV ID:

&6U" K 5 G'H<9' -B7 -8 9BH GD97 -A9B DC @MA -7 FC6-5 @

- Yes □ No □ Unknown

26b. WAS THE INCIDENT SPECIMEN TESTED FOR ESBL PRODUCTION OR OTHER BETA-LACTAMASE GENES?

- Yes □ No □ Laboratory not testing □ Unknown

&6c" IF TESTED, WHAT TESTING METHOD WAS USED3 (Check all that apply):

- Broth Microdilution (ATi detection) □ ESBL well □ Expert rule (ATi flag) □ Unknown □ Broth Microdilution (Manual) □ Disk Diffusion □ E-test □ Molecular test (specify): □ Gene variant (specify): □ Other non-molecular test (specify):

&6d" IF TESTED, WHAT WAS THE RESULT:

- Positive □ Negative □ Indeterminate □ Unknown (repeated for multiple tests)



2+ "GI G7 9DH6 =GHMF9GI @HG.

Please complete the table below based on the information found in the indicated data source. Shaded antibiotics are required to have the MIC entered into the MuGSI-CM system, if available

8 UH Gci fVW	Medical Record		Microscan		Vitek		Phoenix		Sensititre		Kirby-Bauer		E-test	
5 bhjVchjW	A 7	... bhfd	A 7	... bhfd	A 7	... bhfd	A 7	... bhfd	MIC	Interp	Zone Diam	Interp	MIC	Interp
5 a j_UWj b														
5 a cl jW j b#`Uj i`UbUH Y														
5 a d jW j b														
5 a d jW j b#Gi`VUWUa														
5 nfYcbUa														
7 YZJnc`j b														
7 9: 9D=A9														
7 YZXYfcVc`														
7 9: CH5 L=A9														
7 YZ: l j j b														
7 9: H5 N8=A9														
7 YZUhjXja Y# j jVUWUa														
7 YZc`cnUbY#HuncVUWUa														
7 9: HF=5 LCB9														
7 Yd\ Uch j b														
7 jdfcZcl Uj b														
7 C @GH=B														
8 CF=D9 B9 A														
8 cl nWwVj bY														
9 fUj UWwVj bY														
9 FH5 D9 B9 A														
: cgZ: a nVj b														
; YbHLa jVj b														
=A=D9 B9 A														
=a j dYbYa !fY VUWUa														
@j cZcl Uj b														
A9 FCD9 B9 A														
A YfcdYbYa !j UVcfVUWUa														
A jbcWwVj bY														
B jfcZ fUhc j b														
Ca UXUWwVj bY														
D j dYf Uj j b#HuncVUWUa														
D`Unca jVj b														
DC @MML-B`6														
F jZLa d j b														
HYf UWwVj bY														
H; 97 M7 @B9														
Hc VfLa nVj b														
Trimethoprim-sulfamethoxazole														

28a. WAS CASE FIRST IDENTIFIED THROUGH AUDIT? Yes No

28b. CRF STATUS: Complete Pending Chart unavailable after 3 requests

28c. SO INITIALS: _____

28d. DATE OF ABSTRACTION: _____

28e. COMMENTS: _____